Sökning: "non-alcoholic fatty liver disease"
Visar resultat 6 - 10 av 31 avhandlingar innehållade orden non-alcoholic fatty liver disease.
6. Understanding the genetic architecture of fatty liver disease
Sammanfattning : Non-alcoholic fatty liver disease (NAFLD) is currently the most common chronic liver disease, ranging from simple steatosis to more severe conditions, namely non-alcoholic steatohepatitis (NASH), liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). NAFLD has a strong genetic component, and its heritability depends on environmental factors and ethnicity. LÄS MER
7. MST3 and MST4: Critical Regulators of Liver Lipid Partitioning and Hepatocarcinogenesis
Sammanfattning : Non-alcoholic fatty liver disease (NAFLD) encompasses a disease spectrum ranging from hepatic steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and finally cirrhosis. With no approved pharmacological treatment, NAFLD is currently the most common etiology of chronic liver disease in Western countries and its prevalence continues to grow. LÄS MER
8. The role of MBOAT7 on fatty liver disease
Sammanfattning : Non-alcoholic fatty liver disease (NAFLD) is the main health disorder in internal medicine, affecting one third of the population worldwide. Environmental and genetic factors contribute to NAFLD susceptibility and progression. LÄS MER
9. Translational genetics identifies a novel target to treat fatty liver disease
Sammanfattning : Fatty liver disease (FLD) is rapidly prevailing as the most common liver disease worldwide, with an estimated of one-quarter of the global population affected. Environmental and genetic determinants contribute to FLD susceptibility. LÄS MER
10. Microbial modulation of metabolic diseases
Sammanfattning : The gut microbiota, the ensemble of microorganisms living in the gastrointestinal tract, and the host have a mutualist relationship. Alterations of this delicate equilibrium can lead to changes in microbiota composition and/or function leading to the onset of metabolic diseases (e.g., type 2 diabetes and non-alcoholic fatty liver diseases). LÄS MER